RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

RAPT Ther­a­peu­tics is of­fer­ing the first look at Phase II da­ta sug­gest­ing that adding its small mol­e­cule CCR4 an­tag­o­nist to Keytru­da is lead­ing to hoped-for re­spons­es — even in pa­tients who oth­er­wise wouldn’t be ex­pect­ed to re­spond. And it’s now look­ing for a part­ner to help take the pro­gram for­ward.

Among 20 pa­tients with non-small cell lung can­cer who were PD-L1 pos­i­tive (de­fined as TPS ≥1%) and had not re­ceived pri­or check­point in­hibitor ther­a­py, FLX475 plus Keytru­da spurred a con­firmed ob­jec­tive re­sponse rate (ORR) of 40%. Bro­ken down by sub­groups, the ORR is high­er in those with TPS ≥50%, at 50%; and low­er in those with low­er PD-L1 ex­pres­sion (TPS 1-49%), at 38%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER